In2Pharma
  • Home
  • Services
    • Regulatory Affairs
    • Quality Assurance
    • Publicity and Compliance
    • Medical writing & training
    • Vigilance
  • About Us
  • News
  • Contact
Select Page
Falsified Medicines Directive: end of transition period and beginning of monitoring activities

Falsified Medicines Directive: end of transition period and beginning of monitoring activities

by In2Pharma | Nov 4, 2019 | News

Belgium From 9 February  2019, all prescription and reimbursable medicines on the market must bear safety features. At each link in the distribution chain, the safety features must be checked so that the authenticity of the medicine upon delivery can be guaranteed....

Recent Posts

  • Reminder – update RD pregabalin/gabapentin
  • Updated deontological code animal health pharma.be
  • Cover letter variation submission
  • IML Updates Code of Ethics and Hospitality Thresholds
  • Guidance FAMHP on premiums and benefits

Follow Us

  • Facebook
  • LinkedIn
An IQVIA Business

IQVIA Logo
IQVIA is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries and is dedicated to delivering actionable insights and accelerating innovations.

www.iqvia.com

Contact Us

Privacy Policy | Your Privacy Choices | Cookie Policy | BTW BE 895730662 | +32 16 89 16 00| info@in2pharma.com |Terloonststraat 22, 1910 Kampenhout, België